ClinicalTrials.gg
RecruitingNCT05627219Updated Oct 29, 2026

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network

An observational study in Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8 and Stage IIIC Prostate Cancer AJCC v8, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Thomas Jefferson University · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 29, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Prostatic Neoplasms by Thomas Jefferson University — 4 open to participants now, 7 under way, 2 of them phase 3. Prostatic Neoplasms · Thomas Jefferson University.

Started
2024
with 1 other
Observational
3 of 14
1 open now
Registered
9th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Thomas Jefferson University, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 9th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 14 studies in Prostatic Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by Thomas Jefferson University, or all of them as a file.
02

Study summary

This trial evaluates whether a network of peer genetic coaches is useful for addressing disparities in genetic testing and screening among African American men with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). While genetic testing has become central to prostate cancer care, African American men are less likely seek testing due to lack of awareness, cultural beliefs, financial limitations, fear of discrimination, and mistrust in the healthcare system. A network of peer genetic coaches may help address barriers, beliefs, and needs of African American men in the community and provide navigation to increase engagement in genetic testing.

Read the detailed description

PRIMARY OBJECTIVES:

I. Identify and train 6 African American (AA) men as peer genetic coaches (PGCs) for the Extending Prostate Genetic Awareness, Navigation, and Delivery (EXPAND) Network. (Train peer genetic coaches) II. Conduct a feasibility study of peer genetic coaching. (Provide individual coaching)

SECONDARY OBJECTIVE:

I. Patient-related outcomes will include change in decisional conflict for genetic counseling, acceptability/attitude toward genetic counseling and testing, and change of genetics knowledge.

OUTLINE:

AIM 1: Peer genetic coaches undergo training and education on study.

AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study.

03

Conditions studied

  • Metastatic Prostate Carcinoma
  • Stage IIIB Prostate Cancer AJCC v8
  • Stage IIIC Prostate Cancer AJCC v8
  • Stage IV Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Men who have experience with both prostate cancer (PCA) and genetic counseling and testing, as well as peer education or navigation experience. African American men with a history of prostate cancer or with a strong family history of prostate cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AIM 1: Are 18 years old or older
  • AIM 1: Are able to read and speak English comfortably
  • AIM 1: Men who have experience with both prostate cancer (PCA) and genetic counseling and testing will be a priority for training, as well as men who have considerable peer education or navigation experience
  • AIM 2: Are 18 years old or older
  • AIM 2: Are African American
  • AIM 2: Are able to read and speak English comfortably
  • AIM 2: Men who meet any one of the following criteria: (1) prostate cancer; (2) prostate cancer with high-risk features (T3 or higher, Gleason 8 or higher, node positive disease); (3) with or without a diagnosis of prostate cancer with strong family history (2 or more first-degree or second-degree relatives) with prostate cancer (particularly metastatic prostate cancer or died from prostate cancer), breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer

Exclusion criteria

Exclusion Criteria:

  • Patients that do not meet the inclusion criteria
  • Children under the age of 18
  • Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Supportive care (training, education, discussion)

    AIM 1: Peer genetic coaches undergo training and education on study. AIM 2: Patients receive an educational booklet and attend a discussion with a peer genetic coach on study.

    Behavioral: Training and Education · Other: Educational Intervention · Procedure: Discussion

Interventions

  • BehavioralTraining and Education

    Undergo training and education

  • OtherEducational Intervention

    Receive educational booklet

    Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

  • ProcedureDiscussion

    Attend discussion with peer genetic coach

    Also known as: Discuss

06

What researchers measure

Primary outcomes

  1. Number of inquiries to the central number (feasibility)

    Time frame: Up to 1 year

  2. Percent of callers screened and eligible to participate (feasibility)

    Time frame: Up to 1 year

  3. Percent of eligible callers who enroll in the study (feasibility)

    Time frame: Up to 1 year

  4. Percent who complete the endpoint assessment (feasibility)

    Time frame: Up to 1 year

  5. Number and percent of men making genetic counseling appointments

    Time frame: Up to 1 year

Secondary outcomes

  1. Change in decisional conflict for genetic counseling

    Reported with mean and standard deviation.

    Time frame: Baseline up to 1 year

  2. Change in acceptability/attitude toward genetic counseling and testing

    Reported with mean and standard deviation.

    Time frame: Baseline up to 1 year

  3. Change of genetics knowledge

    Reported with mean and standard deviation

    Time frame: Baseline up to 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jul 2027, 37 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 37 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Jul 2027 and completion Sep 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 25, 2022
StartActual
Jun 3, 2024
Primary completionEst.
Jul 2027was Sep 2026
CompletionEst.
Jul 30, 2027was Sep 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Jul 2027
Oct 29, 2026
Study completion
Sep 30, 2026→Jul 30, 2027
Oct 29, 2026
Contact
Study contact changed: a•••@jefferson.edu · •••7739→O•••@jefferson.edu · •••9151. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, United StatesContact •••7739→•••9151Contact a•••@jefferson.edu→O•••@jefferson.edu
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Sep 30, 2026→Jul 2027
    Study completion Sep 30, 2026→Jul 30, 2027
    Contact Study contact changed: a•••@jefferson.edu · •••7739→O•••@jefferson.edu · •••9151. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, United StatesContact •••7739→•••9151Contact a•••@jefferson.edu→O•••@jefferson.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05627219
Responsible party
Sponsor
First posted
Nov 25, 2022
Start date
Jun 3, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Site Public Contact
Contact
ONCTrialNow@jefferson.edu
215-600-9151
Amy Leader, DrPh, MPH
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion